Saltar al contenido

This Week in Dermatology — Jul 24, 2026

25 de julio de 2026 · 8 min

Notas del episodio

Editor's Pick: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials (Nature medicine, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in. We begin with major advances in systemic therapies for inflammatory conditions and cutaneous oncology.

This week's papers:

  1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.. Nature medicine 2026
  2. Clinical and Dermoscopic Triage of head and neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions.. Journal of the American Academy of Dermatology 2026
  3. Comparative effects of interventions for rosacea across phenotype-relevant outcomes: a systematic review and network meta-analysis.. Journal of the American Academy of Dermatology 2026
  4. Insulin Resistance is Not a Predictor of Response to Low-Dose Oral Metformin Therapy in Patients with CCCA: A Retrospective Review.. Journal of the American Academy of Dermatology 2026
  5. Magnified ultraviolet-induced fluorescence dermatoscopy for assessing mite viability in scabies.. Journal of the American Academy of Dermatology 2026
  6. Initial Psychometric Validation of the Caregiver Atopic Dermatitis Control Tool.. Clinical and experimental dermatology 2026
  7. High Level of Uncertainty in Assigning Causative Medications in Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Cohort Analysis.. Journal of the American Academy of Dermatology 2026
  8. A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.. Pediatric dermatology 2026
  9. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.. The British journal of dermatology 2026
  10. Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution.. Clinical and experimental dermatology 2026

Listen at AudioScholar

Todos los episodios de AudioScholar Dermatology Weekly (India)

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.